BRPI0414927A - antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos - Google Patents
antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticosInfo
- Publication number
- BRPI0414927A BRPI0414927A BRPI0414927-0A BRPI0414927A BRPI0414927A BR PI0414927 A BRPI0414927 A BR PI0414927A BR PI0414927 A BRPI0414927 A BR PI0414927A BR PI0414927 A BRPI0414927 A BR PI0414927A
- Authority
- BR
- Brazil
- Prior art keywords
- antagonists
- fibrosis
- alfavbeta6
- agents
- integrins
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 5
- 102000006495 integrins Human genes 0.000 title abstract 4
- 108010044426 integrins Proteins 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 230000003510 anti-fibrotic effect Effects 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 4
- 230000004761 fibrosis Effects 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100031168 CCN family member 2 Human genes 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 abstract 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 abstract 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 230000003352 fibrogenic effect Effects 0.000 abstract 1
- 210000004024 hepatic stellate cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000000651 myofibroblast Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03022048 | 2003-10-01 | ||
| PCT/EP2004/010396 WO2005039547A1 (en) | 2003-10-01 | 2004-09-16 | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414927A true BRPI0414927A (pt) | 2006-11-07 |
Family
ID=34486055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414927-0A BRPI0414927A (pt) | 2003-10-01 | 2004-09-16 | antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070117849A1 (ko) |
| EP (1) | EP1667668B1 (ko) |
| JP (1) | JP4912881B2 (ko) |
| KR (1) | KR101191068B1 (ko) |
| CN (1) | CN100462068C (ko) |
| AR (1) | AR045960A1 (ko) |
| AT (1) | ATE399542T1 (ko) |
| AU (1) | AU2004283413B2 (ko) |
| BR (1) | BRPI0414927A (ko) |
| CA (1) | CA2540730C (ko) |
| DE (1) | DE602004014795D1 (ko) |
| DK (1) | DK1667668T3 (ko) |
| ES (1) | ES2308227T3 (ko) |
| MX (1) | MXPA06003477A (ko) |
| PL (1) | PL1667668T3 (ko) |
| RU (1) | RU2388472C2 (ko) |
| WO (1) | WO2005039547A1 (ko) |
| ZA (1) | ZA200603427B (ko) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003100033A2 (en) | 2002-03-13 | 2003-12-04 | Biogen Idec Ma Inc. | ANTI-αvβ6 ANTIBODIES |
| GB0722650D0 (en) * | 2007-11-19 | 2007-12-27 | Ge Healthcare Ltd | Novel imaging method |
| CN101497656B (zh) * | 2009-03-09 | 2012-08-15 | 东南大学 | 与整合素αvβ3具有高结合活性的多肽及其应用 |
| GB0922014D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
| WO2013148316A1 (en) * | 2012-03-29 | 2013-10-03 | Biogen Idec Ma Inc. | Biomarkers for use in integrin therapy applications |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| CN104640857B (zh) | 2012-07-18 | 2017-07-04 | 圣路易斯大学 | 作为整合素拮抗剂的β氨基酸衍生物 |
| RS56711B1 (sr) | 2013-02-07 | 2018-03-30 | Scifluor Life Sciences Inc | Fluorirani antagonisti integrina |
| US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| SG11201805387RA (en) | 2015-12-30 | 2018-07-30 | Univ Saint Louis | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |
| EA201991124A1 (ru) * | 2016-11-08 | 2019-10-31 | ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV | |
| KR102510858B1 (ko) * | 2016-11-08 | 2023-03-15 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민 |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CN116712540A (zh) | 2016-12-14 | 2023-09-08 | 比奥拉治疗股份有限公司 | 使用整联蛋白抑制剂治疗胃肠道疾病 |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
| CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK11732001A3 (sk) * | 1999-02-20 | 2002-04-04 | Merck Patent Gmbh | Deriváty beta-alanínu |
| DE19933173A1 (de) * | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| DE10006139A1 (de) * | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
| DE10063173A1 (de) * | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
| JP2004536786A (ja) * | 2001-03-02 | 2004-12-09 | メディミューン，インコーポレイテッド | インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法 |
| DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
-
2004
- 2004-09-16 ES ES04765296T patent/ES2308227T3/es not_active Expired - Lifetime
- 2004-09-16 WO PCT/EP2004/010396 patent/WO2005039547A1/en active IP Right Grant
- 2004-09-16 US US10/574,215 patent/US20070117849A1/en not_active Abandoned
- 2004-09-16 AU AU2004283413A patent/AU2004283413B2/en not_active Ceased
- 2004-09-16 MX MXPA06003477A patent/MXPA06003477A/es active IP Right Grant
- 2004-09-16 BR BRPI0414927-0A patent/BRPI0414927A/pt active Search and Examination
- 2004-09-16 AT AT04765296T patent/ATE399542T1/de active
- 2004-09-16 RU RU2006114395/15A patent/RU2388472C2/ru not_active IP Right Cessation
- 2004-09-16 CA CA2540730A patent/CA2540730C/en not_active Expired - Fee Related
- 2004-09-16 PL PL04765296T patent/PL1667668T3/pl unknown
- 2004-09-16 DE DE602004014795T patent/DE602004014795D1/de not_active Expired - Lifetime
- 2004-09-16 EP EP04765296A patent/EP1667668B1/en not_active Expired - Lifetime
- 2004-09-16 JP JP2006529991A patent/JP4912881B2/ja not_active Expired - Fee Related
- 2004-09-16 KR KR1020067006141A patent/KR101191068B1/ko not_active IP Right Cessation
- 2004-09-16 DK DK04765296T patent/DK1667668T3/da active
- 2004-09-16 CN CNB2004800286709A patent/CN100462068C/zh not_active Expired - Fee Related
- 2004-10-01 AR ARP040103571A patent/AR045960A1/es not_active Application Discontinuation
-
2006
- 2006-04-28 ZA ZA200603427A patent/ZA200603427B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007507440A (ja) | 2007-03-29 |
| CA2540730C (en) | 2012-08-21 |
| KR20060090818A (ko) | 2006-08-16 |
| CN1863520A (zh) | 2006-11-15 |
| EP1667668A1 (en) | 2006-06-14 |
| KR101191068B1 (ko) | 2012-10-15 |
| DE602004014795D1 (de) | 2008-08-14 |
| RU2006114395A (ru) | 2007-11-27 |
| RU2388472C2 (ru) | 2010-05-10 |
| DK1667668T3 (da) | 2008-09-15 |
| AU2004283413A1 (en) | 2005-05-06 |
| EP1667668B1 (en) | 2008-07-02 |
| PL1667668T3 (pl) | 2008-10-31 |
| AR045960A1 (es) | 2005-11-16 |
| CA2540730A1 (en) | 2005-05-06 |
| ES2308227T3 (es) | 2008-12-01 |
| ZA200603427B (en) | 2007-09-26 |
| JP4912881B2 (ja) | 2012-04-11 |
| CN100462068C (zh) | 2009-02-18 |
| WO2005039547A1 (en) | 2005-05-06 |
| MXPA06003477A (es) | 2006-06-05 |
| US20070117849A1 (en) | 2007-05-24 |
| ATE399542T1 (de) | 2008-07-15 |
| AU2004283413B2 (en) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414927A (pt) | antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos | |
| WO2006015368A3 (en) | Molecules with effects on cellular development and function | |
| DE60138403D1 (de) | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten | |
| NO20055211L (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
| AU313179S (en) | Sprocket | |
| DE60033837D1 (de) | Inerte cermet-anode zur verwendung in der elektrolytischen herstellung von metallen | |
| AU313180S (en) | Sprocket | |
| ITMI20000106A0 (it) | Composizione che inibisce la formazione di incrostazioni e/o la corrosione | |
| DE50307886D1 (de) | Leitungsführungseinheit zur aktiven führung von leitungen, kabeln oder dergleichen | |
| DE602004026522D1 (de) | Target für Elektronstrahlverdampfung und Verfahren zur dessen Herstellung. | |
| WO2003010336A3 (de) | Molekulare marker beim hepatozellulären karzinom | |
| DE602004022028D1 (de) | Konsistenz verleihende milchsäurebakterien | |
| RS54185B1 (en) | USE OF 24-ORDER | |
| DE60143274D1 (de) | Salzbadnitrierungsverfahren zur herstellung von eisenelementen mit verbesserter korrosionsbeständigkeit und eisenteile | |
| PT1553942E (pt) | Composicao farmaceutica associando tenatoprazol e um anti-inflamatorio | |
| GB2419186C (en) | Method to measure the effect of topically applied agents using skin maintained in organ culture. | |
| ITMI20030985A1 (it) | Elemento costruttivo composito, in particolare per la realizzazione di strutture di parete per edifici e procedimento per la sua fabbricazione. | |
| RS51534B (en) | NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT | |
| DE602004031232D1 (de) | Bohr-/walzverfahren bei der herstellung von nahtlosen rohren | |
| DE10081707T1 (de) | Verfahren zur Herstellung von Stahlblech für Schattenmasken mit ausgezeichneter Dickengenauigkeit in Längsrichtung | |
| ATE374947T1 (de) | Bestimmung freier fraktionen | |
| ATE390479T1 (de) | Modifizierte zellen und ihre verwendungen, insbesondere zur herstellung von steroidderivate | |
| ES1053756Y (es) | Estructura para revestimiento de suelos y paredes. | |
| ITUD20030024A1 (it) | Trave portante di tipo misto acciaio-cemento e relativo procedimento di realizzazione. | |
| ITVA20050029U1 (it) | Arawall, sistema che consente la realizzazione di setti portanti o opere da gettare in cemento armato, con assemblaggio rapido dei casseri isolanti all'armatura e il recupero del sistema di fissaggio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 7.5 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA. |
|
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2437 DE 19/09/2017 POR TER SIDO INDEVIDA, UMA VEZ QUE O PEDIDO FOI ARQUIVADO (DESPACHO 11.5, SEM PETICIONAMENTO DE RECURSO ADMINISTRATIVO) EM 18/04/2017 |
|
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |